autologous iCASP9-CD19-expressing T lymphocytes

{
  "id": "MLC-T-ONC-011659",
  "term": "autologous iCASP9-CD19-expressing T lymphocytes",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that are transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19 and the inducible suicide gene human caspase 9 (iCASP9 or iC9), that is linked to a drug binding domain, with potential immunomodulating and antineoplastic activities. The iCASP9 construct consists of the entire coding sequence for the human FK506-drug binding protein (FKBP12) with an F36V mutation (FKBP12-F36V) that is linked to the gene encoding iC9, which is a modified form of the CASP9 gene where the sequences encoding the endogenous caspase activation and recruitment domains have been deleted. Upon intravenous administration, autologous iCASP9-CD19-expressing T lymphocytes (iC9-CAR19 T-cells) target and bind to CD19-expressing tumor cells, thereby selectively lysing these tumor cells. If the administered T cells cause unacceptable side effects, the chemical homodimerizer AP1903, which binds to the FKBP12-F36V drug-binding domain, can be administered; this induces caspase 9 expression, and results in apoptosis of the administered iC9-CAR19 T cells. The CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.",
  "abbreviation": "autologous iC9-CARCD19 T cells",
  "synonyms": [
    "autologous iC9-CARCD19 T cells",
    "ATLCAR.CD19",
    "autologous ATL-iC9-CAR-CD19",
    "autologous iC9-CART19 cells",
    "autologous iC9-CAR19 cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-icasp9-cd19-expressing-t-lymphocytes/"
}